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Although a number of antiviral drugs inhibit replication of Epstein-Barr virus (EBV) in cell culture, and
acyclovir (ACV) suppresses replication in vivo, currently available drugs have not proven effective for treat-
ment of EBV-associated diseases other than oral hairy leukoplakia. Benzimidazole riboside compounds
represent a new class of antiviral compounds that are potent inhibitors of human cytomegalovirus (HCMV)
replication but not of other herpesviruses. Here we characterize the effects of two compounds in this class
against lytic replication of EBV induced in a Burkitt lymphoma cell line latently infected with EBV. We
analyzed linear forms of EBV genomes, indicative of lytic replication, and episomal forms present in latently
infected cells by terminal probe analysis followed by Southern blot hybridization as well as the high-molecular-
weight unprocessed viral DNA by pulsed-field gel electrophoresis. D-Ribofuranosyl benzimidazole compounds
that act as inhibitors of HCMV DNA maturation, including BDCRB (5,6-dichloro-2-bromo-1-b-D-ribofurano-
syl-1H-benzimidazole), did not affect the accumulation of high-molecular-weight or monomeric forms of EBV
DNA in the induced cells. In contrast, the generation of linear EBV DNA as well as precursor viral DNA was
sensitive to the L-riboside 1263W94 [5,6-dichloro-2-(isopropylamino)-1-b-L-ribofuranosyl-1H-benzimidazole].
The 50% inhibitory concentration range for 1263W94 was 0.15 to 1.1 mM, compared with 10 mM for ACV. Thus,
1263W94 is a potent inhibitor of EBV. In addition, 1263W94 inhibited the phosphorylation and the accumu-
lation of the essential EBV replicative cofactor, early antigen D.
Benzimidazole riboside compounds with potent anti-human
cytomegalovirus (HCMV) activity have recently been charac-
terized (6, 22, 23, 36, 68, 69, 74). BDCRB (5,6-dichloro-2-
bromo-1-b-D-ribofuranosyl-1H-benzimidazole [Fig. 1]) is a D-
riboside compound that works by a unique mechanism,
namely, inhibition of maturation of HCMV through potential
targeting of a viral endonucleolytic activity necessary for pro-
cessing of precursor DNA. Inhibition results in accumulation
of unprocessed high-molecular-weight (HMW) forms of viral
DNA which can be detected by pulsed-field gel electrophoresis
(PFGE). The target of BDCRB has been identified as the
HCMV UL89 gene product, a putative viral terminase (73).
BDCRB is specific for HCMV; no other viruses tested thus far
are inhibited by BDCRB (5, 22, 68, 69).
L-Riboside benzimidazole analogs of BDCRB were synthe-
sized to improve metabolic stability while retaining activity
against HCMV. 1263W94 is a benzimidazole L-riboside with
selective anti-HCMV activity. It is not active against herpes
simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella-
zoster virus, or murine cytomegalovirus by plaque reduction
assay, nor is it active against human immunodeficiency virus or
hepatitis B virus (6). The compound has a 50% inhibitory
concentration (IC50) of 0.04 to 0.1 mM against the AD169
laboratory strain of HCMV, with a similar range of 0.03 to
0.132 mM against HCMV clinical isolates (36). In addition,
1263W94 has .50% oral bioavailability in monkeys and rats
and no toxic effects in monkeys dosed at 180 mg/kg for 30 days
(74). 1263W94 inhibits HCMV replication by a novel mecha-
nism: although viral DNA synthesis is inhibited, the viral DNA
polymerase is not the target (6).
Compounds that inhibit replication of EBV in vitro include
adenine arabinoside (3, 11), phosphonoformic acid, and phos-
phonoacetate (16, 60, 63, 77), a class of halogenated nucleoside
analogs exemplified by FIAC [1-(2-fluoro-2-deoxy-b-D-arabino-
furanosyl)-5-iodocytosine] (42, 46), BVDU [E-5-(2-bromovinyl)-
29-deoxyuridine) (43, 44), ganciclovir (39), acyclovir (ACV)
(12, 24, 45), and the phosphonated nucleoside analogs HPMPC
{(S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine} and re-
lated compounds (40, 41). Nucleoside analogs and the pyrophos-
phate analogs phosphonoformic acid and phosphonoacetate in-
hibit replication of most or all of the herpesviruses. The mode
of action of the nucleosides is via inhibition of the virally
encoded herpesvirus DNA polymerases by the triphosphory-
lated metabolites. None of the compounds affects latent infec-
tion.
EBV infection of B cells is predominantly latent; only a
subset of viral genes is expressed (38). In latently infected cells,
the EBV genome is maintained as a closed circular episome (1,
51, 53) which is replicated by host DNA polymerase. In con-
trast, during productive infection, the viral DNA polymerase
synthesizes large numbers of linear genomes (52). Latently
infected B lymphocytes can be induced by cross-linking of
surface immunoglobulin (64, 65) to trigger the switch to pro-
ductive lytic infection. The D-riboside BDCRB and the L-riboside
1263W94 [5,6-dichloro-2-(isopropylamino)-1-b-L-ribofuranosyl-
1H-benzimidazole (Fig. 1)] were tested for activity against
EBV in a latently infected Burkitt lymphoma (BL) cell line in
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which viral reactivation and lytic replication can be efficiently
induced (64, 65). Here we show that BDCRB was not effective
in blocking either replication or maturation of EBV DNA;
however, viral replication was highly sensitive to 1263W94.
This compound inhibited both the accumulation and phos-
phorylation of the essential EBV replicative cofactor early
antigen D (EA-D), the product of the BMRF1 gene, a DNA
processivity factor which is essential for EBV lytic replication.
MATERIALS AND METHODS
Compounds. BDCRB was synthesized at the University of Michigan and has
been previously described (22, 68, 69). 1263W94 was synthesized at Glaxo Well-
come Co. Thymidine phosphorylase (TPase) and ACV were supplied by Glaxo
Wellcome Co.
Virus and cells. Akata is a type 1 BL cell line latently infected with EBV (64,
65). DG75 is an EBV-negative BL line (2). Lymphocyte lines were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco BRL,
Gaithersburg, Md.) and antibiotics, at 37°C in a 5% CO2 atmosphere. For viral
reactivation studies, Akata cells were treated with anti-human immunoglobulin
G (0.1 mg/ml; Sigma, St. Louis, Mo.) to cross-link surface receptor. For transient
assays, 0.5 ml of DG75 cells (107 cells) were transfected by electroporation with
a Bio-Rad (Hercules, Calif.) Gene Pulser at 320 V and 925 mF.
Plasmids. Plasmid Xho1.9 contains EBV sequence adjacent to the terminal
repeat region and has been previously described (57). EcoRI-C contains the
EcoRI C fragment of EBV cloned into Mua3 vector (56). Both plasmids were
generous gifts from Nancy Raab-Traub. pSG5 vector was purchased from Strat-
agene (La Jolla, Calif.). pSG5-BMRF1, a gift from David Dorsky, contains the
BclI-BglII fragment from the EBV BamH M fragment cloned into pSG5 (79).
pCMVZ contains EBV Z cDNA in the pGEM2-based vector pHD1013 (79).
PFGE. Cells were harvested following 72 h of treatment with compound and
were washed with phosphate-buffered saline (PBS) solution. Akata cells (107)
were resuspended in 45 ml of PBS, mixed with 45 ml of 1.6% low-melting-point
agarose (FMC, Rockland, Maine), pipetted into preformed wells (Bio-Rad), and
chilled. The agarose plug was incubated for 48 h at 48°C in lysis buffer (0.5 M
EDTA [pH 9.0], 1% sodium sarcosyl, 0.5 mg of proteinase K per ml) and then
transferred to storage buffer (10 mM Tris [pH 7.5], 50 mM EDTA) prior to
PFGE. Electrophoresis was performed as described previously (73) for 20 h at
14°C with a linear ramping pulse of 60 to 90 s through 120°C (Bio-Rad CHEF
Mapper). Gels were UV-irradiated (Stratalinker; Stratagene) and then incu-
bated in 0.5 M NaOH–1.5 M NaCl to denature the DNA. DNA was transferred
to Nytran membrane (Schleicher & Schuell, Keene, N.H.), and Southern blot
analysis was performed. Hybridization was carried out with nick-translated DNA
probe Eco-C (56) overnight at 42°C. The membranes were rinsed in 23 SSC (13
SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and then washed with 0.13
SSC–0.1% sodium dodecyl sulfate (SDS) for 30 min at 42°C and twice for 30 min
at 65°C. The dried filters were analyzed by autoradiography with a Molecular
Dynamics PhosphorImager.
Terminal probe analysis. Akata cells were harvested following 72 h of treat-
ment with compound and were washed in PBS. The cells were resuspended in
300 ml of DNA digestion buffer (100 mM NaCl, 10 mM Tris [pH 7.9], 25 mM
EDTA, 0.5% SDS, 0.1 mg of proteinase K per ml) and incubated for 20 h at 48°C.
Next, 100 mg of RNase A was added, and incubation was continued for 2 h at
37°C. The DNA was extracted with phenol-chloroform-isoamyl alcohol (25:24:1)
and then precipitated with 1 ml of isopropyl alcohol. Terminal probe analysis was
performed essentially as described previously (57). Briefly, DNA was digested
overnight with BamHI, and 10 mg of DNA was separated by gel electrophoresis
(0.7% agarose, 13 Tris-borate-EDTA) for 20 h at 50 V. The gel was incubated
in denaturing buffer (1.5 M NaCl, 0.5 N NaOH) for 30 min and then incubated
in neutralization buffer (1.5 M NaCl, 1 M Tris [pH 7.4]) for 30 min. The DNA
was blotted onto a nitrocellulose membrane, and hybridization was performed as
described above. The filters were hybridized at 45°C with a 32P-labeled riboprobe
prepared by transcription of HindIII-digested plasmid Xho1.9 with SP6 RNA
polymerase (Promega, Madison, Wis.).
Northern blot analysis. Total RNA was prepared from Akata cells with an
RNeasy kit (Qiagen, Hilden, Germany); 25 mg of RNA was used for Northern
blot analysis. Probes were prepared by random priming; 100 ng of EA-D, Z, or
actin cDNA was labeled with [32P]dCTP with a Prime-It II kit as specified by the
manufacturer (Stratagene). Actin cDNA was purchased from Clontech (Palo
Alto, Calif.). EA-D was prepared by digestion of pSG5 EA-D with BamHI and
BglII (79). Z cDNA was prepared by digesting cytomegalovirus Z with EcoRI
and XbaI (79). EA-D and Z cDNAs were gel purified (Qiaex II, Qiagen) prior to
labeling.
Western blot analysis. Cells were harvested, washed with PBS, and then
resuspended in ELB1 buffer (0.25 M NaCl, 0.1% Nonidet P-40, 0.05 M HEPES
[pH 7.0], 0.001 M phenylmethylsulfonyl fluoride, 0.005 EDTA, 0.5 mM dithio-
threitol). The sample was lysed by freeze-thawing three times, and the superna-
tant was collected following centrifugation at 13,000 3 g for 15 min at 4°C. The
protein concentration of the supernatant was determined with the Bradford
reagent (Bio-Rad). For Western analysis, equal amounts of protein were sepa-
rated by SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred
to an Immobilon membrane (Millipore, Bedford, Mass.). The membrane was
probed with antibody to the following proteins as indicated in the figure legends:
EA-D (catalog no. C65026M; Biodesign, Kennebunk, Maine), Z (BZ-1; Dako,
Glostrup, Denmark), R (8C12; Argene S.A. Varilhes, France), actin (clone
AC-15; Sigma), or interferon response factor 1 (IRF-1) (sc497-X; Santa Cruz
Biotechnology, Santa Cruz, Calif.). The membranes were washed for three times
for 10 min each with TBST buffer (0.9% NaCl, 0.02 M Tris [pH 7.5], 0.05%
Tween 20), then probed with the appropriate secondary antibody (horseradish
peroxidase-conjugated anti-mouse or anti-rabbit; Amersham, Arlington Heights,
Ill.), and washed again with TBST. The reaction was visualized by enhanced
chemiluminescence (Amersham).
Phosphatase assay. Cell lysate (20 mg) was digested with 2,000 U of lambda
phosphatase in a volume of 50 ml for 3 h at 30°C as specified by the manufacturer
(New England Biolabs, Beverly, Mass.). The samples were analyzed by SDS-
PAGE followed by immunoblotting as described above.
RESULTS
1263W94, but not BDCRB, inhibits EBV replication. Akata
cells were induced by cross-linking of surface immunoglobulin;
then compounds were added, and incubation continued for
72 h. The cells were harvested, and DNA was analyzed by
PFGE followed by Southern blot hybridization with an EBV-
specific probe, Eco-C. Two forms of viral DNA were detected;
monomeric DNA represents the unit-length (172-kbp) EBV
genome, consisting of both linear and episomal DNA, and
HMW DNA represents the unprocessed precursor viral DNA.
The appearance of nicked DNA results from partial digestion
of HMW DNA (73). An increase in monomeric DNA, repre-
senting newly synthesized linear viral genomes, was detected
upon induction of the cells (Fig. 2; compare lanes 6 and 7).
Increasing amounts of 1263W94 inhibited the appearance of
both forms of EBV DNA (lanes 2 to 5). In contrast, BDCRB
at a high dose (20 mM) (lane 1) inhibited the appearance of
neither monomeric nor HMW DNA, unlike its effect on
HCMV (73). The amount of hybridized monomer DNA was
quantitated by PhosphorImager analysis. IC50 values calcu-
lated by PFGE analysis in several experiments were 0.15 to 1.1
mM for 1263W94, compared with 10 mM for ACV.
1263W94 is more active than ACV against EBV replication.
Terminal probe analysis was used to measure inhibition of
EBV viral DNA replication, as it easily distinguishes between
the circular, latent form of the viral genome and linear repli-
cative forms (57). Increasing amounts of 1263W94 (Fig. 3,
lanes 1 to 4) or ACV (lanes 5 to 9) were added to Akata cells
immediately after induction and incubated for 72 h. The sam-
ples were harvested, and viral DNA was analyzed as described
above. Ladder arrays of bands, which represent linear genomic
FIG. 1. Structures of benzimidazole ribosides. BDCRB is the 2-substituted
derivative of the compound DRB (5,6-dichloro-1-[b-D-ribofuranosyl) benzimid-
azole] (66, 67). The synthesis and activity of BDCRB have been described
elsewhere (22, 68, 69). The compound 1263W94 differs from BDCRB in that it
contains an L-sugar group and has a substitution of an isopropylamino group for
bromine at the 2 position of the benzimidazole ring. Neither compound is
phosphorylated in vitro or in vivo (5, 6).
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forms of newly replicated EBV DNA, were detected in the
IgG-induced cells (lanes 11 and 12) but not in the sample from
uninduced cells (lane 10). Linear genomes were reduced by
more than 50% with 0.6 mM 1263W94 (lane 3) or with 25 mM
ACV (lane 6). This result confirms the PFGE results, namely,
that 1263W94 is more effective than ACV in inhibiting EBV
DNA replication. None of the EBV DNA replication forms
was inhibited by 20 mM BDCRB (data not shown).
The medium of samples receiving ACV was pretreated with
TPase for 1 h at 37°C (2 U/ml), followed by filter sterilization.
Thymidine, which is present in bovine serum, can compete with
ACV for uptake into the cell, decreasing the effectiveness of
the drug (15). TPase did not affect viral replication induced by
anti-IgG treatment (Fig. 3, lane 12).
1263W94 inhibits the appearance of EBV EA-D. The EBV
early gene BMRF1 encodes EA-D, a processivity factor for the
viral DNA polymerase (71). Detection of EA-D is commonly
used as a marker for EBV lytic reactivation. Total cellular
lysate was prepared from induced Akata cells incubated for
72 h in the presence of increasing amounts of drug. As ex-
pected, EA-D was detected in the induced cells (Fig. 4A, lane
1) but not in uninduced cells (lane 2), indicating that the
uninduced cells are tightly latent and efficiently induced by IgG
antibody. Surprisingly, 1263W94 affected the appearance of
EA-D in this and other assays in a dose-dependent manner
(Fig. 4A [lanes 3 to 7] 4B [lanes 1 to 4]). This effect was specific
for 1263W94 as the amount of EA-D protein was not de-
creased after the addition of ACV (Fig. 4B, lanes 5 to 9), even
at levels of ACV which completely inhibited viral DNA repli-
cation (25 to 100 mM ACV [Fig. 3, lanes 5 and 6). The decrease
in EA-D protein was probably not due to inhibition of viral
DNA replication, as levels were similarly reduced 12 h follow-
ing induction (data not shown), well before the peak of viral
DNA replication in induced Akata cells (14). The addition of
TPase to samples containing ACV (Fig. 3) did not affect EA-D
protein levels.
1263W94 does not inhibit transcription of EA-D. As EA-D
protein levels were reduced in the presence of 1263W94, we
analyzed BMRF1 (EA-D) RNA by Northern blot analysis (Fig.
5). BMRF1 RNA levels were not lower in samples incubated
with 5 mM 1263W94 (Fig. 5, lanes 7 to 11) than in control
samples (lanes 2 to 6). Therefore, the reduced levels of EA-D
protein do not correlate with decreased RNA levels. In con-
trast, BMRF1 RNA levels increased in the presence of ACV
(lanes 12 to 16).
Since BMRF1 promoter activity is regulated by the viral
immediate-early gene products R and Z (29, 32), these two
proteins could be potential targets for 1263W94. Therefore we
also measured levels of R and Z RNAs. R and Z are tran-
scribed from two separate promoters located in the immediate-
early region of the EBV genome. One, Rp, encodes two bicis-
tronic transcripts of 4.0 and 3.3 kb, each of which contains the
entire coding sequence for Z and R. A second promoter, Zp,
encodes a 1.0-kb BZLF1 transcript (4, 47). There was no sig-
nificant change in the levels of the 1.0-kb (BZLF1) or 3.3- or
4.0-kb (BRLF1/BZLF1) RNA in samples incubated with
1263W94 (Fig. 5, lanes 6 to 11) compared with samples which
FIG. 2. The L-riboside 1263W94 inhibits replication of EBV DNA. Induced
Akata cells were incubated in the presence or absence of drug for 72 h and then
harvested. Samples were prepared, and PFGE was performed to detect viral
replication. EBV DNA was detected by hybridization with 32P-labeled EcoRI C
fragment of EBV. HMW and monomer forms of DNA were quantitated follow-
ing PhosphorImager analysis. A band representing nicked HMW DNA (p) mi-
grates to the resolution limit of the gel.
FIG. 3. 1263W94 inhibits replication of EBV. Akata cells were induced by
IgG cross-linking and incubated in the presence or absence of drug for 3 days.
Cells were harvested, and terminal probe analysis was performed as described in
the text. DNA was digested with BamHI, separated on a 0.7% agarose gel, then
transferred to nitrocellulose, and probed with 32P-labeled riboprobe Xho1.9
containing sequences specific for the EBV terminal repeat region. Samples
containing ACV were incubated in the presence of TPase.
FIG. 4. 1263W94 inhibits appearance of EBV EA-D. Akata cells were in-
duced by cross-linking with IgG and incubated in the presence or absence of
1263W94 for 3 days. Cells were harvested, and total protein lysate was prepared
for immunoblot analysis; 30 mg of lysate were separated on an SDS–9% poly-
acrylamide gel, transferred to Immobilon, and probed with an EA-D-specific
antibody. Detection was by enhanced chemiluminescence.
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did not receive compound (lanes 2 to 6). Surprisingly, there
was a significant increase in R and Z RNAs in the samples
treated with ACV (lanes 12 to 16), and this effect may account
for the increase in EA-D RNA.
1263W94 inhibits phosphorylation of EA-D. Since EA-D
RNA levels were unaffected by 1263W94, we investigated the
stability of EA-D protein. Akata cells were induced and then
incubated with compounds as indicated for 24 h. Next, cyclo-
heximide was added to a final concentration of 50 mg/ml, and
samples were harvested at 0, 2, 6, and 12 h after cycloheximide
addition. Equivalent amounts of protein lysate were used for
immunoblot analysis.
Overall, EA-D protein levels were lower in the presence of
1263W94 (Fig. 6A, lanes 7 to 10) than in the controls (lanes 2
to 5). However, the most striking observation is the virtual
disappearance of the more slowly migrating form(s) of EA-D
in the samples treated with 1263W94 (lanes 7 to 10). This form
of EA-D appeared less stable in the presence of 1263W94. It
has been previously shown, by 32P labeling, that multiple phos-
phorylated forms of EA-D exist in lytically infected cells (76);
this result suggested that 1263W94 may inhibit the phosphor-
ylation of EA-D and that this form of the protein may be less
stable in the presence of 1263W94.
To confirm that HMW EA-D bands were phosphorylated
forms of the protein, we treated the control lysate sample
(used in lane 2) with lambda phosphatase. The slowly migrat-
ing form of EA-D protein was resolved into a more rapidly
migrating band in the presence of phosphatase (Fig. 6D), con-
firming that EA-D is differentially phosphorylated.
The amount of R protein, but not Z protein, was also slightly
reduced in the presence of 1263W94 (Fig. 6B). Occasionally, a
reduction in the levels of Z protein was also noted; however,
these differences were not consistently seen at this level (5 mM)
of drug (data not shown), and the decrease was not as dramatic
as that noted for EA-D. In contrast, the amounts of Z and R
proteins were increased by addition of ACV as expected, as
increased levels of RNA were also observed (Fig. 5). To con-
firm that the cycloheximide block was effective, 0- and 2-h
lysate samples were probed for IRF-1, a short-lived cellular
protein (28, 75). IRF-1 was abundant at 0 h but virtually dis-
appeared by 2 h following addition of cycloheximide (data not
shown).
EA-D is poorly phosphorylated in an EBV-negative cell line.
Next, we determined the phosphorylation status of EA-D in an
EBV-negative cell line, DG75. DG75 cells were transfected
with pSG5 vector (Fig. 7, lane 1) or an expression plasmid
pSG5-EA-D and incubated without compound (lane 2) or with
5 mM 1263W94 (lane 3). Cells were harvested 24 h after trans-
FIG. 5. 1263W94 does not inhibit the transcription of EA-D or the immedi-
ate-early genes R and Z. Akata cells were induced and then incubated in the
absence of drug or with 5.0 mM 1263W94 or 50 mM ACV. Samples were
harvested at times postinduction (p.i.), and total RNA was prepared. Northern
blot analysis was performed with radiolabeled probes specific for EA-D, Z, or
actin.
FIG. 6. 1263W94 inhibits the phosphorylation of EA-D. Akata cells were
induced, and compound was immediately added. The samples were incubated for
24 h, then cycloheximide (CHX) was added to a final concentration of 50 mg/ml,
and incubation was continued. Samples were harvested at the times indicated
after addition of cycloheximide. Whole-cell lysates were prepared, and protein
was quantitated by the Bradford method; 50 mg of each sample were separated
on an SDS–10% polyacrylamide gel, and the protein was transferred to an
Immobilon membrane. The membrane was probed with antibodies specific for
EA-D (A), R (B), Z (C), or actin (D). (E) Akata cell lysates induced for 24 h (20
mg) were incubated with lambda phosphatase for 3 h at 30°C. The samples were
separated by SDS-PAGE and then probed for EA-D as described above. un,
untreated.
FIG. 7. EA-D is underphosphorylated in DG75 cells. DG75 cells (107) were
transfected with 5 mg of pSG5 vector (lane 1) or pSG5-BMRF1, with (lane 3) or
without (lane 2) the addition of 5 mM 1263W94. Cells were harvested 24 h after
transfection, and protein lysates were prepared. Akata cells (lanes 4 and 5) were
induced by IgG cross-linking, and lysates were prepared from cells harvested 24 h
postinduction. Following SDS-PAGE separation, the proteins were transferred
and then probed with EA-D antibody as described in the text. Lane 5 is a shorter
exposure of lane 4. Size at the left is indicated in kilodaltons.
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fection, and protein lysate was analyzed by Western blotting
for EA-D along with control lysates from 24-h-induced Akata
cells (lanes 4 and 5). Multiple forms of EA-D are detected in
cells transfected with EA-D plasmid. However, the most highly
phosphorylated form(s) of EA-D, which is readily detectable in
induced Akata cells (54 kDa, lanes 4 and 5), is not present in
the transfected cells (lanes 2 and 3). These data suggest that
EA-D may be phosphorylated to some extent by a cellular
kinase; however, further phosphorylation of EA-D involves a
virally encoded kinase, a virally induced kinase, or possibly a
cellular kinase which is induced by IgG cross-linking.
EA-D phosphorylation is temporally regulated in Akata
cells. Since the data suggested that EA-D might be regulated
in part by phosphorylation, we examined the kinetics of EA-D
phosphorylation in induced Akata cells. EA-D phosphoryla-
tion appears to be temporally regulated following induction of
the lytic cycle (Fig. 8). At 12 h postinduction, EA-D is pre-
dominantly hyperphosphorylated (lane 2). However, by 24 h
approximately half of the total EA-D is unphosphorylated
(lane 3), and by 48 h virtually all of the protein is unphosphor-
ylated. This finding expands upon a previous report which
shows that multiple forms of EA-D occur 9 and 12 h postin-
duction, concurrent with the initiation of viral DNA synthesis
(14). These data suggest that EA-D function might be regu-
lated in part by phosphorylation.
DISCUSSION
The L-riboside 1263W94 is a potent inhibitor of EBV DNA
replication, with an IC50 of 0.15 to 1.1 mM, at least 10-fold
more potent than ACV in identical assays. The toxicity (50%
tissue culture inhibitory dose) of 1263W94 was determined for
several lymphocyte lines, IM-9, MOLT4, and U937, and varied
from 55 to 90 mM. Therefore, the in vitro therapeutic index for
1263W94 is 50 to 100 in this assay system. Phase I trials in
asymptomatic human immunodeficiency virus-positive volun-
teers show that the drug is well tolerated at these levels, with
no adverse side effects (74).
In contrast, another HCMV inhibitor, the D-riboside BDCRB,
was ineffective against EBV replication. In contrast to its ac-
tivity against HCMV, neither inhibition of processing of EBV
precursor DNA nor inhibition of formation of linear genomes
was detected. This difference in antiviral selectivity may be due
to the lack of identity between HCMV UL89, a putative ter-
minase which is the target for BDCRB, and its EBV homolog,
BD/BGRF1, at a single critical residue (73).
EA-D is a component of the EBV DNA polymerase com-
plex (9, 35, 72) and is essential for EBV lytic replication (25,
27). The protein functions as a DNA processivity factor (8, 71).
In addition, EA-D is a nonspecific DNA-binding protein (70)
and has transactivator function. EA-D transactivates the pro-
moter for the BHLF1 gene through a GC-rich element which
is also an essential element of the lytic origin of replication
(ori-Lyt) (78, 79). As EA-D is essential for viral lytic replica-
tion, functional inactivation of this protein would inhibit viral
DNA synthesis.
1263W94 appeared to inhibit both the accumulation and the
phosphorylation of EA-D, but it is not clear at this point if
these two observations are related or are due to different
effects of the drug. EA-D protein, but not RNA, levels were
consistently decreased. As this decrease was noted at early
times after induction, the reduction in EA-D protein levels are
unlikely to be due to the effects of a replication block. It is
possible that translation initiation is inhibited or that newly
synthesized EA-D is rapidly degraded in the presence of the
compound. In addition, the accumulation of a hyperphosphor-
ylated form of EA-D was selectively inhibited, and this form of
the protein specifically appeared to be less stable in the pres-
ence of the compound. This may contribute to the overall
reduced levels of EA-D. These possibilities are now being
investigated to determine the mechanism underlying these ob-
servations. No decrease in EA-D was detected in cells treated
with ACV at levels that completely blocked replication. We
frequently also noticed a decrease in the levels of R and Z
proteins in the presence of 1263W94, although not as dramatic
as that observed for EA-D. In addition, the decreased levels of
R and Z did not result in noticeably decreased levels of EA-D
mRNA. At this point it is unclear to what extent the decrease
in R, Z, and EA-D proteins contributes to the antiviral mech-
anism of the compound. In contrast, incubation of cells with 50
mM ACV caused a dramatic increase in the transcription of R,
Z, and EA-D RNAs. The mechanism underlying this increase
remains to be addressed.
As mentioned previously, 1263W94 consistently inhibited
the appearance of hyperphosphorylated forms of EA-D. This
effect implies that a direct or indirect target of the compound
may be a kinase that phosphorylates EA-D. EA-D was phos-
phorylated to low levels in the EBV-negative cell line DG75,
presumably due to a cellular kinase. However, additional hy-
perphosphorylated forms of EA-D appear in lytically induced
Akata cells, suggesting that a viral kinase, or possibly a virally
induced cellular kinase, may be responsible for hyperphosphor-
ylation of EA-D. In addition, we show that EA-D hyperphos-
phorylation is temporally regulated in induced Akata cells,
being readily detected 12 h after induction and decreasing by
48 h. Taken together, these data suggest that phosphorylation
may contribute to the regulation of EA-D activity. Since EA-D
is essential for viral replication, the inhibition of EA-D phos-
phorylation and protein accumulation by 1263W94 may ac-
count for the antiviral effect of the compound.
A putative EBV kinase has been identified based on motifs
present in catalytic domains of protein kinases (62). This gene,
BGLF4, has recently been cloned (26) and homologs have
been identified in the other human herpesviruses (7, 49, 50, 61,
62). These related kinases are in some instances nonessential
for replication in vitro (13, 19, 25, 30, 54) but may be required
for pathogenesis. The HSV homolog, UL13, phosphorylates an
HSV early protein, ICP22 (55), as well as the cellular elonga-
tion factor EF-1d (34) and has been implicated in pathogenesis
in a mouse model (13). Another HSV kinase, US3, was shown
to be required for replication in mice but not in tissue culture
(37). The varicella-zoster virus homolog, open reading frame
47, has recently been shown to be essential for replication in
thymocytes and skin cells (48). Therefore, it is possible that a
virally encoded kinase is responsible for the phosphorylation of
EA-D. BGLF4 has recently been cloned in this laboratory, and
preliminary data suggest that EA-D may be a potential target
for the kinase (26).
The essential role of EA-D in EBV DNA replication has
been appreciated for years. In fact, its homolog in HSV, UL42,
FIG. 8. EA-D phosphorylation is temporally regulated during the lytic cycle.
Akata cells were induced by IgG cross-linking, and samples were harvested at 0,
12, 24, and 48 h postinduction (p.i.). Lysate samples (50 mg) were analyzed for
EA-D protein.
VOL. 73, 1999 BENZIMIDAZOLE L-RIBOSIDE INHIBITOR OF EBV 7275
has been proposed as a target for inhibition of viral replication
because of its specificity (10, 20, 21). Until recently, it was
thought that most EBV-associated malignancies were not good
candidates for antiviral therapy, as they are largely due to
latent EBV infection. However, recent evidence suggests that
in several of these diseases a period of viral replication may
precede and perhaps trigger onset of disease, which raises the
possibility of prophylactic therapy. Expression of viral replica-
tive genes is detected in a subset of cells in B-cell lymphomas,
including posttransplant lymphomas and AIDS-associated
lymphoma (33, 58, 59). Prior to the onset of nasopharyngeal
carcinoma, serum IgA titers to EBV replicative antigens, in-
cluding EA-D, increase in response to viral reactivation at
unknown sites (18, 31).
Currently, prospects for anti-EBV therapy are limited to a
few drugs, all of which target the viral polymerase. Since drug-
resistant mutants to the polymerase gene arise in other her-
pesviruses, and probably EBV, it is possible that cross-resistant
viral mutants will arise during prolonged treatment with such
drugs. Therefore, novel antiviral compounds that target genes
other than herpesvirus polymerases, yet retain antiviral speci-
ficity, are likely to be needed.
In this work, we show that the antiviral compound 1263W94
inhibits EBV replication more effectively than ACV. In addi-
tion, we present evidence that the essential replication factor,
EA-D, may be an ultimate target of the antiviral compound
1263W94, as both the accumulation and phosphorylation of
EA-D are decreased in the presence of the compound. We also
confirm that the phosphorylation of EA-D is temporally reg-
ulated, and propose that a EA-D may be a substrate for a viral
kinase encoded by the BGLF4 ORF. Recently, Davis et al.
mapped HCMV resistance to 1263W94 to the viral kinase,
UL97 (17). Since 1263W94 is effective against both HCMV
and EBV, the effects of the compound on both the HCMV
replication cofactor, UL44, and the viral kinase, UL97, are now
being investigated.
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